Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Drug Profile

Ethinylestradiol/norelgestromin transdermal - Johnson & Johnson

Alternative Names: Contraceptive patch - Johnson & Johnson; Ethinylestradiol/17-deacetyl norgestimate transdermal - Johnson & Johnson; Ethinylestradiol/RWJ 10553; Evra; Evra™; Ortho Evra

Latest Information Update: 22 Apr 2014

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen-Cilag; Ortho-McNeil
  • Class Alkylated estrogenic steroids; Hormonal contraceptives; Norpregnatrienes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 16 Apr 2014 First generic equivalent available in USA for Contraception/Pregnancy (Prevention)
  • 16 Mar 2006 Clinical data from a media release have been added to the adverse events section
  • 17 Nov 2005 Clinical data from a media release have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top